Last reviewed · How we verify

Influenza challenge virus

Imperial College London · Phase 1 active Biologic

Influenza challenge virus is a Biologic drug developed by Imperial College London. It is currently in Phase 1 development.

At a glance

Generic nameInfluenza challenge virus
SponsorImperial College London
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Influenza challenge virus

What is Influenza challenge virus?

Influenza challenge virus is a Biologic drug developed by Imperial College London.

Who makes Influenza challenge virus?

Influenza challenge virus is developed by Imperial College London (see full Imperial College London pipeline at /company/imperial-college-london).

What development phase is Influenza challenge virus in?

Influenza challenge virus is in Phase 1.

Related